SWX:NOVNPharmaceuticals
Is Novartis (SWX:NOVN) Overvalued After Its Recent 20% Year‑to‑Date Share Price Gain?
Novartis (SWX:NOVN) has quietly pushed higher over the past month, adding about 5 %, and is now up roughly 20 % year to date, comfortably outpacing many large pharma peers.
See our latest analysis for Novartis.
That move comes on top of a strong year to date, with a roughly 20 % year to date share price return and a 22 % one year total shareholder return, signaling steady momentum as investors warm to Novartis’ pipeline and earnings profile.
If Novartis’ steady climb appeals to you, this...